当前位置: X-MOL 学术BMC Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
PODXL might be a new prognostic biomarker in various cancers: a meta-analysis and sequential verification with TCGA datasets.
BMC Cancer ( IF 3.8 ) Pub Date : 2020-07-02 , DOI: 10.1186/s12885-020-07108-5
Siying He 1 , Wenjie Du 2 , Menglan Li 1 , Ming Yan 3 , Fang Zheng 1
Affiliation  

Several studies have investigated the associations between the podocalyxin-like protein (PODXL) expression quantity or locations and cancers survival, but the results were far from conclusive. Therefore, we proceeded a meta-analysis on PODXL in various human cancers to find its prognostic value and followed confirmation using the TCGA datasets. We performed a systematic search, and 18 citations, including 5705 patients were pooled in meta-analysis. The results were verified with TCGA datasets. Total eligible studies comprised 5705 patients with 10 types of cancer. And the result indicated that PODXL high-expression or membrane-expression were significantly related to poor overall survival (OS). However, subgroup analysis showed a significant association between high expressed PODXL and poor OS in the colorectal cancer, pancreatic cancer, urothelial bladder cancer, renal cell carcinoma and glioblastoma multiforme. Then, we validated the inference using TCGA datasets, and the consistent results were demonstrated in patients with pancreatic cancer, glioblastoma multiforme, gastric cancer, esophageal cancer and lung adenocarcinoma. The result of meta-analysis showed that high expressed PODXL was significantly linked with poor OS in pancreatic cancer and glioblastoma multiforme, but not in gastric cancer, esophageal cancer or lung adenocarcinoma. And the membrane expression of PODXL might also associate with poor OS. PODXL may act as tumor promotor and may serve as a potential target for antitumor therapy.

中文翻译:

PODXL 可能是各种癌症的新预后生物标志物:使用 TCGA 数据集进行荟萃分析和序贯验证。

几项研究调查了足萼蛋白样蛋白 (PODXL) 表达量或位置与癌症生存之间的关联,但结果远非结论性的。因此,我们对 PODXL 在各种人类癌症中进行了荟萃分析,以发现其预后价值,并使用 TCGA 数据集进行了确认。我们进行了系统检索,并汇总了 18 条引用(包括 5705 名患者)进行荟萃分析。结果通过 TCGA 数据集进行了验证。符合资格的研究共有 5705 名患有 10 种癌症的患者。结果表明,PODXL高表达或膜表达与较差的总生存期(OS)显着相关。然而,亚组分析显示,在结直肠癌、胰腺癌、膀胱尿路上皮癌、肾细胞癌和多形性胶质母细胞瘤中,高表达的 PODXL 与较差的 OS 之间存在显着相关性。然后,我们使用 TCGA 数据集验证了这一推论,并在胰腺癌、多形性胶质母细胞瘤、胃癌、食管癌和肺腺癌患者中得到了一致的结果。Meta分析结果显示,高表达的PODXL与胰腺癌和多形性胶质母细胞瘤的低OS显着相关,但与胃癌、食管癌或肺腺癌无关。PODXL 的膜表达也可能与较差的 OS 相关。PODXL 可能充当肿瘤促进剂,并可能作为抗肿瘤治疗的潜在靶点。
更新日期:2020-07-02
down
wechat
bug